Related Experiment Videos
Pefloxacin therapy for nosocomial infections in the intensive care unit
1Department of Anaesthetics and Medicine, University of Cape Town, South Africa.
Abstract:
Nosocomial infections occurring in an intensive care unit (ICU) are commonly caused by aerobic Gram-negative bacilli or Staphylococcus aureus, which are frequently multi-resistant and difficult to treat and contribute significantly to the patients' morbidity in the ICU. Pefloxacin, with its wide range of antimicrobial activity, lack of serious side-effects and advantageous kinetics, is a useful drug for use in this group of critically ill patients. Pefloxacin has achieved a greater than 70% clinical cure rate and a microbiological response of over 80% in cases of nosocomial pneumonia in the ICU. Failure and superinfection has occurred with the development of resistance, particularly in Pseudomonas aeruginosa in a small number of cases, but this can be prevented by combination antimicrobial therapy. Serious side-effects, including confusion, psychiatric disturbance and other neurological abnormalities were rare and resolved on withdrawal of the drug. Drug interactions occur with cimetidine and theophylline but are usually not clinically relevant; significant interaction with warfarin occurs and the dose of warfarin needs careful adjustment. Pefloxacin is a valuable drug for use in bacteriologically proven sensitive infections and combination with aminoglycosides or beta-lactam agents should prevent the development of resistance.
Insights
Pefloxacin effectively treats intensive care unit (ICU) infections caused by resistant bacteria, showing high cure rates. Combination therapy can prevent resistance, making it a valuable option for critically ill patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Critical Care Medicine
Background:
- Intensive care unit (ICU) nosocomial infections are often caused by multi-resistant Gram-negative bacilli and Staphylococcus aureus.
- These infections significantly increase patient morbidity and are challenging to treat.
- Effective antimicrobial agents are crucial for managing these severe conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of pefloxacin for treating nosocomial infections in ICU patients.
- To assess the clinical and microbiological response rates to pefloxacin therapy.
- To identify potential side effects, drug interactions, and resistance patterns associated with pefloxacin use.
Main Methods:
- Clinical and microbiological data from ICU patients treated with pefloxacin were analyzed.
- Efficacy was measured by clinical cure rates and microbiological response.
- Safety was assessed by monitoring adverse events and drug interactions.
Main Results:
- Pefloxacin demonstrated a clinical cure rate exceeding 70% and a microbiological response over 80% for nosocomial pneumonia.
- Resistance, particularly in Pseudomonas aeruginosa, was observed in a small number of cases, leading to treatment failure or superinfection.
- Serious side effects were rare and reversible; clinically relevant drug interactions were infrequent, except for warfarin, requiring dose adjustment.
Conclusions:
- Pefloxacin is a valuable therapeutic option for bacteriologically confirmed sensitive infections in critically ill ICU patients.
- Combination antimicrobial therapy, particularly with aminoglycosides or beta-lactam agents, is recommended to prevent the development of resistance.
- Careful monitoring for drug interactions, especially with warfarin, is necessary during pefloxacin treatment.